Netrin-1: Focus on its role in cardiovascular physiology and atherosclerosis.

Pathophysiology atherosclerosis cardiology cell biology/structural biology cell signalling/signal transduction mechanism of atherosclerosis/growth factors vascular biology

Journal

JRSM cardiovascular disease
ISSN: 2048-0040
Titre abrégé: JRSM Cardiovasc Dis
Pays: England
ID NLM: 101598607

Informations de publication

Date de publication:
Historique:
received: 01 07 2020
accepted: 27 08 2020
entrez: 7 12 2020
pubmed: 8 12 2020
medline: 8 12 2020
Statut: epublish

Résumé

The netrins form a family of laminin-related proteins which were first described as modulators of cell migration and axonal guidance during fetal development. Netrin-1 is the most extensively studied member of this family and, since its discovery, non-neural roles have been associated with it. Together with its receptors, DCC/neogenin and UNC5, netrin-1 has been shown to be involved in the regulation of angiogenesis, organogenesis, cancer and inflammation. An NF-κB-dependent truncated isoform of netrin-1 has also been shown to be produced in endothelial and some types of cancer cells, which both accumulates in and affects the function of the nucleus. In atherosclerosis, conflicting roles for netrin-1 have been reported on plaque progression via its receptor UNC5b. Whereas endothelial-derived netrin-1 inhibits chemotaxis of leukocytes and reduces the migration of monocytes to the atherosclerotic plaque, netrin-1 expressed by macrophages within the plaque plays a pro-atherogenic role, promoting cell survival, recruiting smooth muscle cells and inhibiting foam cell egress to the lymphatic system. In contrast, there is evidence that netrin-1 promotes macrophage differentiation to an alternative activated phenotype and induces expression of IL-4 and IL-13, while downregulate expression of IL-6 and COX-2. Further work is needed to elucidate the precise roles of the two isoforms of netrin-1 in different cell types in the context of atherosclerosis, and its potential as a putative novel therapeutic target in this disease.

Identifiants

pubmed: 33282228
doi: 10.1177/2048004020959574
pii: 10.1177_2048004020959574
pmc: PMC7691900
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

2048004020959574

Subventions

Organisme : British Heart Foundation
ID : FS/18/69/33884
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RE/18/2/34213
Pays : United Kingdom

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Biochem Cell Biol. 2000;78(5):569-75
pubmed: 11103947
Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16210-5
pubmed: 15520390
Sci Signal. 2012 Aug 07;5(236):ra57
pubmed: 22871610
Nat Immunol. 2012 Jan 08;13(2):136-43
pubmed: 22231519
Am J Respir Crit Care Med. 2010 Apr 15;181(8):815-24
pubmed: 20075388
Cell. 1994 Aug 12;78(3):425-35
pubmed: 8062385
Front Cell Neurosci. 2018 Jul 31;12:221
pubmed: 30108487
Cell. 2011 Apr 29;145(3):341-55
pubmed: 21529710
Science. 2014 Jun 13;344(6189):1275-9
pubmed: 24876346
Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3183-3189
pubmed: 28918114
Gene Expr Patterns. 2003 Jun;3(3):279-83
pubmed: 12799072
Diabetologia. 2003 Jul;46(7):926-33
pubmed: 12819897
Cancer Res. 2014 Jul 15;74(14):3716-26
pubmed: 24812271
Curr Opin Lipidol. 2010 Aug;21(4):305-11
pubmed: 20531184
PLoS One. 2014 Mar 19;9(3):e92311
pubmed: 24647424
Mol Cell. 2009 Mar 27;33(6):692-703
pubmed: 19328064
Cancer Res. 1997 Feb 1;57(3):382-6
pubmed: 9012460
Int J Biochem Cell Biol. 2007;39(5):874-8
pubmed: 17137827
Biomed Res Int. 2016;2016:9582430
pubmed: 27493969
Antioxid Redox Signal. 2010 Apr 15;12(8):1009-59
pubmed: 19686040
J Neurosci. 1999 Jun 15;19(12):4938-47
pubmed: 10366627
PLoS One. 2016 Aug 10;11(8):e0160685
pubmed: 27509208
Cell. 2008 Jun 27;133(7):1241-54
pubmed: 18585357
J Nucleic Acids. 2019 Feb 24;2019:3947123
pubmed: 30923634
J Neurosci. 2004 Dec 1;24(48):10826-34
pubmed: 15574733
Nat Rev Immunol. 2013 Oct;13(10):709-21
pubmed: 23995626
Arterioscler Thromb Vasc Biol. 2019 Jun;39(6):1026-1033
pubmed: 31070478
Science. 1990 Jan 5;247(4938):49-56
pubmed: 2294591
Free Radic Biol Med. 2019 Nov 20;144:266-278
pubmed: 30946962
Nat Med. 2014 Apr;20(4):377-84
pubmed: 24584118
Neuron. 2014 Aug 20;83(4):839-849
pubmed: 25123307
Nature. 1998 Oct 22;395(6704):801-4
pubmed: 9796814
Cell. 1996 Oct 18;87(2):197-204
pubmed: 8861904
Mech Dev. 2000 Aug;96(1):115-9
pubmed: 10940631
Nat Rev Immunol. 2002 Oct;2(10):748-59
pubmed: 12360213
J Immunol. 2010 Sep 15;185(6):3750-8
pubmed: 20693423
Ann Rheum Dis. 2016 Sep;75(9):1706-13
pubmed: 26452536
J Biol Chem. 2013 Jan 25;288(4):2210-22
pubmed: 23195957
Curr Opin Cell Biol. 2004 Oct;16(5):572-9
pubmed: 15363809
Cell. 1999 Jun 25;97(7):927-41
pubmed: 10399920
J Immunol. 2016 Aug 15;197(4):1389-98
pubmed: 27430720
Am J Physiol Renal Physiol. 2013 Apr 1;304(7):F948-57
pubmed: 23408164
Arterioscler Thromb Vasc Biol. 2020 Feb;40(2):462-472
pubmed: 31801376
PLoS One. 2011;6(5):e14812
pubmed: 21625583
Dev Cell. 2003 Mar;4(3):371-82
pubmed: 12636918
J Cell Sci. 2013 Jan 1;126(Pt 1):186-95
pubmed: 23038776
Front Cell Neurosci. 2015 Apr 20;9:146
pubmed: 25941474
Nat Rev Mol Cell Biol. 2007 Apr;8(4):296-306
pubmed: 17356579
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14729-34
pubmed: 16203981
Biochem Biophys Res Commun. 2000 May 10;271(2):287-91
pubmed: 10799289
Br J Pharmacol. 2015 Jul;172(14):3548-64
pubmed: 25824964
EMBO J. 2001 Jun 1;20(11):2715-22
pubmed: 11387206
Mol Immunol. 2018 Nov;103:166-172
pubmed: 30290313
Kidney Int. 2013 Jun;83(6):1087-98
pubmed: 23447066
J Immunol. 2011 Jan 1;186(1):549-55
pubmed: 21098235
Breast Cancer Res Treat. 2003 Jul;80(2):215-20
pubmed: 12908825
Inflammation. 2014 Apr;37(2):573-80
pubmed: 24234226

Auteurs

Vasco Claro (V)

School of Cardiovascular Medicine and Sciences, British Heart Foundation Centre of Research Excellence, King's College London, London, UK.

Albert Ferro (A)

School of Cardiovascular Medicine and Sciences, British Heart Foundation Centre of Research Excellence, King's College London, London, UK.

Classifications MeSH